logo-loader
Eden BioSolutions

Grant of Awards under LTIP PDMR Dealing

RNS Number : 0792V
Eden Research plc
17 September 2026
 

Greenvale AP


 

Eden Research plc

(“Eden” or “Company)

 

Grant of Awards under Long-Term Incentive Plan PDMR Dealing

 

Eden Research plc (AIM: EDEN), a leader in sustainable biopesticide and biocontrol technology, confirms the grant of 33,737,659 options over new Ordinary Shares under the Company’s Long Term Incentive Plan ("LTIP") to its members of staff (“the Options”)

 

Of these 7,101,189 Options have been awarded to Sean Smith, Chief Executive Officer and 5,334,928 have been awarded to Alex Abrey, Chief Finance Officer (together the "Executives"). A further 21,301,542 Options have been issued to other employees.

 

The grant is in respect of CY2025 in order to ensure continuity of long term incentive and is at a strike price of 1p each.

 

Performance conditions

 

  • 50% of the grant is subject to an absolute Total Shareholder Return –(share price plus dividends) condition:
    • This vests in a straight line with 20% of this portion of award vesting at a threshold of 4.36p and increasing up to full vesting at 8.72p;
    • Share price test is volume weighted average for the final 20 trading days of the two year performance period ending on second anniversary of grant;
  • 50% of the grant is subject to revenue performance target to 31 March 2028 (aggregate audited revenue for FY2027 and FY2028)

 

Further terms

 

  • Awards have a ten year life – i.e. a seven year exercise window;
  • Following exercise, 50% of the awards are subject to 6 month holding period;

 

The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further detail.

 

For further information contact:

 

Eden Research plc

www.edenresearch.com

Sean Smith, Chief Executive Officer

Via Walbrook PR

Alex Abrey, Chief Financial Officer

 

 

 

Cavendish Capital Markets Limited (Nominated advisor and joint broker)

Tel: 020 7220 0500

Giles Balleny / Elysia Bough (Corporate Finance)

 

Harriet Ward (Corporate Broking) / Dale Bellis (Sales)

 

 

 

Oberon Capital (Joint Broker)

Tel: 020 3179 5300

Nick Lovering / Mike Seabrook / Adam Pollock

 

 

 

Walbrook PR (Media Relations & Investor Relations)

Tel: 020 7933 8780 or eden@walbrookpr.com

Paul McManus / Nick Rome / Anna Dunphy

Mob: 07980 541 893 / 07748 325 236 / 07876 741 001  

 


 

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

Sean Smith

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Eden Research plc

b)

 

LEI

 

213800ZWTYTVQQSM3J85

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

 

Options over ordinary shares of 1 pence each

 

 

GB0001646941

b)

 

Nature of the transaction

 

Grant of options

c)

 

Price(s) and volume(s)

 

Price(s)

 

Volume(s)

1p

7,101,189

d)

 

Aggregated information

- Aggregated volume

- Price

 

 

 

N/A

e)

 

Date of the transaction

 

16 September 2026

f)

 

Place of the transaction

 

Outside of trading venue

 

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

Alex Abrey

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Financial Officer

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Eden Research plc

b)

 

LEI

 

213800ZWTYTVQQSM3J85

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

 

Options over ordinary shares of 1 pence each

 

 

GB0001646941

b)

 

Nature of the transaction

 

Grant of options

c)

 

Price(s) and volume(s)

 

Price(s)

 

Volume(s)

1p

5,334,928

d)

 

Aggregated information

- Aggregated volume

- Price

 

 

 

N/A

e)

 

Date of the transaction

 

16 September 2026

f)

 

Place of the transaction

 

Outside of trading venue

 

Notes to Editors:

 

Eden Research is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries.

 

Eden's products are formulated with terpene active ingredients, based on natural plant defence metabolites. To date, they have been primarily used on high-value fruits and vegetables, improving crop yields and marketability, with equal or better performance when compared with conventional pesticides. Eden has three products currently on the market:

 

Based on plant-derived active ingredients, Mevalone® is a foliar biofungicide which initially targets a key disease affecting grapes and other high-value fruit and vegetable crops.  It is a useful tool in crop defence programmes and is aligned with the requirements of integrated pest management programmes. It is approved for sale in a number of key countries whilst Eden and its partners pursue regulatory clearance in new territories thereby growing Eden's addressable market globally.

 

Cedroz™ is a bionematicide that targets free living nematodes which are parasitic worms that affect a wide range of high-value fruit and vegetable crops globally.  Cedroz is registered for sale on two continents and Eden's commercial collaborator, Eastman Chemical, is pursuing registration and commercialisation of this important new product in numerous countries globally.

 

Eden's seed treatment product (approval expected in 2026), Ecovelex was developed to safely tackle crop destruction caused by birds - a major cause of losses in maize and other crops. Ecovelex works by creating an unpleasant taste or odour that repels birds, leaving the seeds safely intact and the birds unaffected and free to find alternative food sources. The product is based on Eden's plant-derived chemistry, registered in the EU, US and elsewhere, and formulated using Eden's Sustaine® microencapsulation system.

 

Eden's Sustaine® encapsulation technology is used to harness the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. Sustaine microcapsules are naturally-derived, plastic-free, biodegradable micro-spheres derived from yeast. It is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation.

 

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN. It was awarded the London Stock Exchange Green Economy Mark in January 2021, which recognises London-listed companies that derive over 50% of their total annual revenue from products and services that contribute to the global green economy. Eden derives 100% of its total annual revenues from sustainable products and services.

 

For more information about Eden, please visit:  www.edenresearch.com.

 

Follow Eden on LinkedIn, Twitter and YouTube. 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBSGDCIDBDGLL
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

Eden Research CEO talks revenue growth and latest Ecovelex regulatory win

Eden Research PLC (AIM:EDEN, OTCQB:EDNSF) CEO Sean Smith talked with Proactive's Stephen Gunnion about recent developments, including the company's growth and new regulatory achievements. Smith highlighted the second consecutive approval for Ecovelex in Italy, an important product in their...

on 11/08/2024

6 min read